Abstract

Objective To observe the effect of carvedilol and motoprolol on the weight of cardiac muscle in patients with hypertensive heart disease.Methods One hundred patients with hypertensive heart disease were divided into two groups by random number and treated with carvedilol(n =54) and motoprolol(n =46) respectively for 12 months.Data were recorded (left ventricular end-diastolic dimension (LVEDD),left ventricular end-systolic dimension (LVESD),left ventricular ejection fraction (LVEF),interventricular septal thickness (IVST),and left ventricular posterior wall thickness (LVPWT)) before and after the treatment.Left ventricular muscle mass(LVW),left ventricular mass index(LVWI) were calculated.Results After treatment,both groups improved with declined LVEDD (motoprolol group:(43.60 ± 4.43) mm vs.(46.70 ± 3.21) mm,t =18.143,P < 0.01 ; carvedilol group:(42.50 ± 2.56) mm vs.(46.5 ± 3.18) mm,t =18.232,P < 0.01),thinner IVST (motoprolol group:(9.68 ± 1.65) mm vs.(12.01 ± 1.56) mm,t =12.785,P < 0.01 ; carvedilol group:(9.05 ± 1.04) mm vs.(11.59 ± 1.54) mm,t =7.865,P < 0.01),and increased LVEF (motoprolol group:(52.89 ± 8.78)% vs.(50.23 ± 7.88)%; carvedilol group:(54.65 ± 8.87%)% vs.(50.22 ±7.89)%).In the carvedilol treatment group,LVMI significantly (t =4.987,P < 0.01) declined from (133.75 ±25.89) g/m2 to (109.25 ± 22.53) g/m2.In the motoprolol treatment group,LVMI declined from (134.76 ± 25.87) g/m2 to (119.78 ± 23.65.53) g/m2 (t =5.689,P < 0.01).After the treatment,each index of carvedilol group improved significantly compared with metoprolol group (P < 0.05).Conclusion Both medications are able to reduce the weight of cardiac muscle of patients with hypertensive heart disease,and carvedilol is better than motoprolol. Key words: Carvedilol; Motoprolol ; Hypertensive heart disease; Weight of cardiac muscle

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.